Alzheon raises $10M in series A round

Alzheon Inc. (Framingham, Mass.) raised $10 million in a series A round led by new investor Ally Bridge Group. Undisclosed new and existing investors also participated.

CEO Martin Tolar told BioCentury the company hopes to start a Phase III trial by YE15 of ALZ-801 to treat Alzheimer's disease (AD) patients who are apolipoprotein E epsilon 4 (APOE4)-positive. ...